Dan Ives, Wedbush Securities global head of technology research, joins CNBC's 'Squawk on the Street' to break down ...

Investing.com -- Tesla's stock has faced continued pressure in 2025, but Wedbush analysts remain bullish, maintaining their ...

In a report released today, Yun Zhong from Wedbush maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price ...

U.S. defense stocks opened in the red on Thursday, Feb. 20 following reports that President Donald Trump’s administration has ...

Palantir Technologies received a new Buy rating from Loop Capital and continued bullish support from Wedbush on Thursday, despite recent market concerns over potential U.S. defense budget cuts.

Wedbush made a splash on Tuesday with the announcement that it was entering the ever-growing ETF market. Read more here.

Demand for Nvidia's ( NASDAQ: NVDA) Blackwell GPUs remains much stronger than supply despite the recent DeepSeek noise, ...

Chimerix (NASDAQ:CMRX – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a research note issued to investors on Tuesday,RTT News reports. They ...

Equities research analysts at Wedbush increased their FY2024 earnings per share estimates for shares of Cheesecake Factory in ...

Wedbush analyst Daniel Ives remains highly bullish on Tesla (TSLA) stock despite the concerns surrounding CEO Elon Musk’s ...

Wedbush raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $81 from $77 and keeps an Outperform rating on the shares following the Food and Drug Administration’s approval for ...

We recently compiled a list of the Top 14 AI Stocks on Wall Street: News and Analyst Ratings. In this article, we are going to take a look at where Tesla, Inc. (NASDAQ:TSLA) stands against the ...